Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

While the allogeneic vs autologous debate continues in the cell therapy field, research on in vivo therapies is drawing ...

Chimeric RNAs and the proteins translated from them often have a causal role in tumorigenesis. They are also occasionally found at low levels in healthy cells. These phenomena were previously ...

A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...

Structural and functional analyses identify a new family of bifunctional cell-wall-targeting type VI secretion system (T6SS) effectors and a surface-charge-engineering strategy that expands T6SS ...

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has described proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) ligase binding moiety covalently linked to an ...

The "Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) ...

Microcap Chimeric Therapeutics (ASX:CHM) has confirmed its receipt of a $4.17 million tax rebate from Canberra for R&D activities. The cell therapy tech developer now sits on a >$4M cash injection ...